Bristol Myers Squibb Co BMY
Bristol Myers Squibb Co (NYSE: BMY) is a respiratory drug developer. Its lead program, admilparant, is in Phase 3 for Idiopathic pulmonary fibrosis (IPF).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| admilparant | IPF | small molecule | Phase 3 |
| RYZ101 (225Ac-DOTATATE) | SSTR+ GEP-NETs post Lu177 therapy | radiopharmaceutical | Phase 3 |
| mezigdomide (combination) | Relapsed/refractory multiple myeloma | small molecule | Phase 3 |
| izalontamab brengitecan (iza-bren) | HR+/HER2- breast cancer and EGFR-mutated NSCLC | antibody | Phase 3 |
| obexelimab | IgG4-related disease | antibody | Phase 3 |
| arlo-cel (arlocabtagene autoleucel) | Quadruple-class exposed RRMM | cell therapy | Phase 2 |
| pumitamig | Previously untreated advanced NSCLC | antibody | Phase 2 |
Recent results and decisions
- Oct 26, 2026met PANKU-Lung01 Phase 3 interim analysis showed iza-bren significantly improved median PFS versus platinum-based chemotherapy in EGFR-mutated NSCLC.
Results showed that iza-bren significantly improved median progression-free survival (PFS) compared to PBC.
Filing - Oct 26, 2026met Iza-bren significantly improved median progression-free survival versus platinum-based chemotherapy in the Phase 3 PANKU-Lung01 study for EGFR-mutated NSCLC.
Results showed that iza-bren significantly improved median progression-free survival (PFS) compared to PBC.
Filing - Oct 25, 2026positive ROSETTA Lung-107 trial showed encouraging anti-tumor activity in both squamous and non-squamous NSCLC with manageable safety profile.
Data showed encouraging anti-tumor activity, with responses observed in both squamous and non-squamous NSCLC and across PD-L1 expression levels, together with a manageable safety profile consistent with prior global datasets for pumitamig.
Filing
12 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 respiratory companies
- INSMED Inc INSM
- Liquidia Corp LQDA
- Trevi Therapeutics, Inc. TRVI
- Generate Biomedicines, Inc. GENB
- Savara Inc SVRA
- Apnimed, Inc. APMD
- Inhibikase Therapeutics, Inc. IKT
- Pulmonx Corporation LUNG
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.